Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The vast majority of Cystic Fibrosis (CF) patients worldwide are vitamin D insufficient. There is no evidence of benefit of vitamin D supplementation for CF patients yet. However, descriptive cross-sectional studies suggest that vitamin D might be beneficial with respect to bone health, as well as to the newly described "non-classical" functions of vitamin D such as the potential anti-diabetic and immunomodulatory effects. To prove causation, and to determine which serum vitamin D concentration is optimal for CF patients, vitamin D supplementation interventional studies are needed, such as our trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D and Microbiota in Cystic Fibrosis

NCT02589444

Vitamin D Deficiency Cystic Fibrosis

COMPLETED NA

Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) Patients

NCT00685971

Cystic Fibrosis Vitamin D Deficiency

COMPLETED NA

Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)

NCT01426256

Cystic Fibrosis Respiratory Tract Infections

COMPLETED PHASE3

PK/PD of Vitamin D3 in Adults With CF

NCT03734744

Vitamin D Deficiency Cystic Fibrosis

TERMINATED NA

Vitamin D3 for the Treatment of Low Vitamin D in Cystic Fibrosis

NCT00762918

Cystic Fibrosis Vitamin D Deficiency

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ergocalciferol

Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Group Type EXPERIMENTAL

Supplementation with vitamin D2/D3

Intervention Type DIETARY_SUPPLEMENT

Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.

Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Cholecalciferol

Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Group Type EXPERIMENTAL

Supplementation with vitamin D2/D3

Intervention Type DIETARY_SUPPLEMENT

Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.

Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Control

Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supplementation with vitamin D2/D3

Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.

Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Established diagnosis of cystic fibrosis
* Age 6 years and more
* Serum 25-hydroxy vitamin D concentration at the latest visit \< 75 nmol/L

Exclusion Criteria

* Pregnancy or lactation
* Established diagnosis of CF-related diabetes
* CF-related liver disease
* Status post transplantation (lung, liver or other)
* Long-term corticosteroid treatment per os
* Hypercalcaemia or kidney stones
* Use of tanning beds more often than once a month
* At inclusion, plans to travel to a sunny location for more than 1 week during the study period
* Any known disorders of the endocrine system affecting vitamin D metabolism (hyperparathyroidism, malignancy, advanced renal disease)
* Inclusion into another study testing immunomodulatory substances

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No